Guggenheim raised the firm’s price target on AnaptysBio (ANAB) to $140 from $100 and keeps a Buy rating on the shares. Following positive Phase I data for ANB033, the firm added its valuation in celiac disease and other indications and it additionally estimates Jemperli royalties to be worth $45 per share, the analyst tells investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- AnaptysBio price target lowered to $55 from $70 at Barclays
- AnaptysBio price target lowered to $56 from $80 at Stifel
- AnaptysBio Files Legal Complaint Against GSK and Tesaro
- Buy Rating for AnaptysBio Amid Legal Dispute with Tesaro Over Jemperli Rights
- AnaptysBio Sues TESARO Over License Agreement Breach